高级检索
当前位置: 首页 > 详情页

miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal transition in colon cancer cells.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]The Third Hospital of Hebei Medical University, Shijiazhuang, China
出处:
ISSN:

关键词: miR-424-5p epithelial–mesenchymal transition 5-fluorouracil resistance colon cancer Src focal adhesion kinase

摘要:
miR-424-5p negatively regulates various malignant biological behaviours in tumour cells. We explored the relationship between miR-424-5p and 5-fluorouracil resistance in colon cancer cells. We developed 5-fluorouracil-resistant HT-29 cells and detected miR-424-5p expression using real-time fluorescence quantitative PCR. Cell viability was assessed using Cell Counting Kit-8 (CCK-8) assay. Immunofluorescence and western blotting were performed to determine protein levels. Apoptosis was detected by Annexin V-FITC/PI staining. miR-424-5p was downregulated in 5-fluorouracil-resistant HT-29 cells. A miR-424-5p mimic enhanced the sensitivity of the resistant cells to 5-fluorouracil, whereas a miR-424-5p inhibitor promoted 5-fluorouracil resistance in HT-29 cells. Furthermore, the miR-424-5p mimic downregulated vimentin and upregulated E-cadherin in 5-fluorouracil-resistant HT-29 cells, whereas the miR-424-5p inhibitor exhibited opposite effects. The miR-424-5p inhibitor significantly inhibited 5-fluorouracil-induced HT-29 cell apoptosis and Src and focal adhesion kinase phosphorylation, whereas the miR-424-5p mimic showed opposite effects. Pretreatment with Src inhibitor 1 or focal adhesion kinase inhibitor 2 blocked the increase in Src and focal adhesion kinase phosphorylation and vimentin expression level and the decrease in E-cadherin expression level in miR-424-5p inhibitor-exposed HT-29 cells. miR-424-5p suppressed epithelial-mesenchymal transition by inhibiting the Src/focal adhesion kinase signalling pathway to reduce 5-fluorouracil resistance in colon cancer cells. © The Author(s) 2021. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2021]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
通讯作者:
通讯机构: [1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]The Third Hospital of Hebei Medical University, Shijiazhuang, China [*1]The Fourth Hospital of Hebei Medical University, Shijiazhuang 050051, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号